Dr. Robert E. Burr, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 177
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
NH license 40015 -
Physician Nutrition Specialist (Internal Medicine)
NH license 40015
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Licking Memorial Hospital Newark, OH
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 177
- Services billed
- 444
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Hemoglobin a1c level | 51 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 34 | 27 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 15 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mounjaro (tirzepatide) Other prescribers in Lebanon, NH | 136 |
| Jardiance (empagliflozin) Other prescribers in Lebanon, NH | 126 |
| Ozempic (semaglutide) Other prescribers in Lebanon, NH | 66 |
| Trulicity (dulaglutide) Other prescribers in Lebanon, NH | 59 |
| Tresiba Flextouch U-200 (insulin degludec) Other prescribers in Lebanon, NH | 58 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Lebanon, NH | 51 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Lebanon, NH | 39 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Lebanon, NH | 35 |
| Synjardy Xr (empagliflozin/metformin hcl) Other prescribers in Lebanon, NH | 35 |
| Levothyroxine Sodium Other prescribers in Lebanon, NH | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 6 payments worth $124 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $48.80 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $23.66 |
| Insulet Corporation | $20.50 |
| Lilly USA, LLC | $15.75 |
| Novo Nordisk Inc | $15.06 |
| Food and Beverage | $124 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $25,260 in research payments for these studies, mostly to the institutions running them.
- A master protocol for a randomized, controlled, clinical trial of multiple pharmacologic agents in adult participants with metabolic dysfunction-associated steatotic liver disease who are at increased risk of developi…
Eli Lilly and Company - A phase 2, randomized, open-label, comparator-controlled trial to evaluate the efficacy and safety of LY3938577 in study participants, with type 2 diabetes mellitus previously treated with basal insulin
Eli Lilly and Company - A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Eli Lilly and Company · Recruiting · NCT07165028 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Ov…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.